Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Harrow Health ( (HROW) ) is now available.
Harrow reported first-quarter 2026 results on May 11, 2026, highlighting strong demand across its ophthalmic portfolio despite lower reported revenue of $44.2 million, down from $47.8 million a year earlier, and a wider net loss of $27.6 million. The quarter was affected by an $8 million non-recurring gross-to-net revenue adjustment tied to new commercial coverage for dry eye drug VEVYE, which management said establishes a profitable recurring patient base and positions the company for improved financial performance beginning in the second quarter.
VEVYE delivered record new and total prescriptions, surpassed Xiidra on a monthly total prescription basis with about 14% market share, and is on track to generate over $100 million in 2026 revenue despite an 18% decline in the branded dry eye market. Additional growth came from anesthetic IHEEZO, with unit demand up 18% year over year and strong uptake in retina accounts, and from steroid TRIESENCE, where demand more than doubled and has now grown for six consecutive quarters, supporting Harrow’s reaffirmed full-year 2026 revenue guidance of $350 million to $365 million and second-quarter revenue expectations of $71 million to $81 million.
The most recent analyst rating on (HROW) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
Spark’s Take on HROW Stock
According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.
The score is held down primarily by leveraged financials and weak/volatile cash flow conversion, plus bearish technical trends. These negatives are partly offset by a positive earnings-call outlook with strong 2026 growth and EBITDA guidance, while recent debt financing improves liquidity but increases leverage risk.
To see Spark’s full report on HROW stock, click here.
More about Harrow Health
Harrow Inc., listed on Nasdaq as HROW, is a North American provider of ophthalmic disease management solutions, offering a broad portfolio targeting front- and back-of-the-eye conditions such as dry eye disease, neovascular age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface and retinal disorders. The company focuses on delivering safe, effective, and accessible medications aimed at improving patient compliance and clinical outcomes.
Average Trading Volume: 706,587
Technical Sentiment Signal: Buy
Current Market Cap: $1.42B
For a thorough assessment of HROW stock, go to TipRanks’ Stock Analysis page.